Digital Repository

The third intensive care bundle with blood pressure reduction in acute cerebral haemorrhage trial (INTERACT3): an international, stepped wedge cluster randomised controlled trial

Show simple item record

dc.contributor.author Ma, L.
dc.contributor.author Hu, X.
dc.contributor.author Song, L.
dc.contributor.author Chen, X.
dc.contributor.author Ouyang, M.
dc.contributor.author Billot, L.
dc.contributor.author Li, Q.
dc.contributor.author Malavera, A.
dc.contributor.author Li, X.
dc.contributor.author Muñoz-Venturelli, P.
dc.contributor.author de Silva, A.
dc.contributor.author Thang, N.H.
dc.contributor.author Wahab, K.W.
dc.contributor.author Pandian, J.D.
dc.contributor.author Wasay, M.
dc.contributor.author Pontes-Neto, O.M.
dc.contributor.author Abanto, C.
dc.contributor.author Arauz, A.
dc.contributor.author Shi, H.
dc.contributor.author Tang, G.
dc.contributor.author Zhu, S.
dc.contributor.author She, X.
dc.contributor.author Liu, L.
dc.contributor.author Sakamoto, Y.
dc.contributor.author You, S.
dc.contributor.author Han, Q.
dc.contributor.author Crutzen, B.
dc.contributor.author Cheung, E.
dc.contributor.author Li, Y.
dc.contributor.author Wang, X.
dc.contributor.author Chen, C.
dc.contributor.author Liu, F.
dc.contributor.author Zhao, Y.
dc.contributor.author Li, H.
dc.contributor.author Liu, Y.
dc.contributor.author Jiang, Y.
dc.contributor.author Chen, L.
dc.contributor.author Wu, B.
dc.contributor.author Liu, M.
dc.contributor.author Xu, J.
dc.contributor.author You, C.
dc.contributor.author Anderson, C.S.
dc.contributor.author INTERACT3 Investigators
dc.date.accessioned 2023-06-08T05:04:50Z
dc.date.available 2023-06-08T05:04:50Z
dc.date.issued 2023
dc.identifier.citation Lancet.2023; 402(10395):27-40[ Epub 2023 May 25]. Erratum in: Lancet. 2023; 402(10397):184. en_US
dc.identifier.issn 0140-6736
dc.identifier.uri http://repository.kln.ac.lk/handle/123456789/26363
dc.description indexed in MEDLINE. en_US
dc.description.abstract BACKGROUND: Early control of elevated blood pressure is the most promising treatment for acute intracerebral haemorrhage. We aimed to establish whether implementing a goal-directed care bundle incorporating protocols for early intensive blood pressure lowering and management algorithms for hyperglycaemia, pyrexia, and abnormal anticoagulation, implemented in a hospital setting, could improve outcomes for patients with acute spontaneous intracerebral haemorrhage. METHODS: We performed a pragmatic, international, multicentre, blinded endpoint, stepped wedge cluster randomised controlled trial at hospitals in nine low-income and middle-income countries (Brazil, China, India, Mexico, Nigeria, Pakistan, Peru, Sri Lanka, and Viet Nam) and one high-income country (Chile). Hospitals were eligible if they had no or inconsistent relevant, disease-specific protocols, and were willing to implement the care bundle to consecutive patients (aged ≥18 years) with imaging-confirmed spontaneous intracerebral haemorrhage presenting within 6 h of the onset of symptoms, had a local champion, and could provide the required study data. Hospitals were centrally randomly allocated using permuted blocks to three sequences of implementation, stratified by country and the projected number of patients to be recruited over the 12 months of the study period. These sequences had four periods that dictated the order in which the hospitals were to switch from the control usual care procedure to the intervention implementation of the care bundle procedure to different clusters of patients in a stepped manner. To avoid contamination, details of the intervention, sequence, and allocation periods were concealed from sites until they had completed the usual care control periods. The care bundle protocol included the early intensive lowering of systolic blood pressure (target <140 mm Hg), strict glucose control (target 6·1-7·8 mmol/L in those without diabetes and 7·8-10·0 mmol/L in those with diabetes), antipyrexia treatment (target body temperature ≤37·5°C), and rapid reversal of warfarin-related anticoagulation (target international normalised ratio <1·5) within 1 h of treatment, in patients where these variables were abnormal. Analyses were performed according to a modified intention-to-treat population with available outcome data (ie, excluding sites that withdrew during the study). The primary outcome was functional recovery, measured with the modified Rankin scale (mRS; range 0 [no symptoms] to 6 [death]) at 6 months by masked research staff, analysed using proportional ordinal logistic regression to assess the distribution in scores on the mRS, with adjustments for cluster (hospital site), group assignment of cluster per period, and time (6-month periods from Dec 12, 2017). This trial is registered at Clinicaltrials.gov (NCT03209258) and the Chinese Clinical Trial Registry (ChiCTR-IOC-17011787) and is completed. FINDINGS: Between May 27, 2017, and July 8, 2021, 206 hospitals were assessed for eligibility, of which 144 hospitals in ten countries agreed to join and were randomly assigned in the trial, but 22 hospitals withdrew before starting to enrol patients and another hospital was withdrawn and their data on enrolled patients was deleted because regulatory approval was not obtained. Between Dec 12, 2017, and Dec 31, 2021, 10 857 patients were screened but 3821 were excluded. Overall, the modified intention-to-treat population included 7036 patients enrolled at 121 hospitals, with 3221 assigned to the care bundle group and 3815 to the usual care group, with primary outcome data available in 2892 patients in the care bundle group and 3363 patients in the usual care group. The likelihood of a poor functional outcome was lower in the care bundle group (common odds ratio 0·86; 95% CI 0·76-0·97; p=0·015). The favourable shift in mRS scores in the care bundle group was generally consistent across a range of sensitivity analyses that included additional adjustments for country and patient variables (0·84; 0·73-0·97; p=0·017), and with different approaches to the use of multiple imputations for missing data. Patients in the care bundle group had fewer serious adverse events than those in the usual care group (16·0% vs 20·1%; p=0·0098). INTERPRETATION: Implementation of a care bundle protocol for intensive blood pressure lowering and other management algorithms for physiological control within several hours of the onset of symptoms resulted in improved functional outcome for patients with acute intracerebral haemorrhage. Hospitals should incorporate this approach into clinical practice as part of active management for this serious condition. FUNDING: Joint Global Health Trials scheme from the Department of Health and Social Care, the Foreign, Commonwealth & Development Office, and the Medical Research Council and Wellcome Trust; West China Hospital; the National Health and Medical Research Council of Australia; Sichuan Credit Pharmaceutic and Takeda China. en_US
dc.language.iso en en_US
dc.publisher Elsevier en_US
dc.subject Blood Pressure en_US
dc.title The third intensive care bundle with blood pressure reduction in acute cerebral haemorrhage trial (INTERACT3): an international, stepped wedge cluster randomised controlled trial en_US
dc.type Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search Digital Repository


Browse

My Account